TITLE

Screening Blood Donors for Hereditary Hemochromatosis: Decision Analysis Model Comparing Genotyping to Phenotyping

AUTHOR(S)
Adams, Paul C.; Valberg, Leslie S.
PUB. DATE
June 1999
SOURCE
American Journal of Gastroenterology;Jun1999, Vol. 94 Issue 6, p1593
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: The identification of a gene for hereditary hemochromatosis in 69-100% of typical hemochromatosis patients has resulted in a genotypic test to identify persons with the typical missense mutation. Population screening by genotyping has the potential to reduce screening costs because of a high specificity of the genetic test. METHODS: Decision analysis techniques are used to compare the outcome, utility, and incremental cost savings of a plan to screen voluntary blood donors and their siblings for hemochromatosis using a genotypic test (C282Y mutation) with phenotypic tests (transferrin saturation, serum ferritin). RESULTS: Genotypic screening is less expensive than phenotypic screening only if the cost of the initial genetic test is less than $20. The screening program saves money (dominant strategy) if the cost of the initial genetic test is less than $28. Incremental cost saving declines as the cost of the gene test increases. At a gene test cost of $173, it costs $109,358 to identify a homozygote with potential life-threatening illness, Incremental cost saving also declines as the penetrance of the hemochromatosis gene in the population screened decreases. Phenotypic screening with confirmatory genetic testing results in a cost of $2,711 per homozygote with life-threatening complications. CONCLUSIONS: Population screening programs for hemochromatosis have the potential to save money. Optimal strategies for screening include initial testing for iron overload (phenotyping) with confirmatory genetic testing, or initial genetic testing if the test is less than $28.
ACCESSION #
16444899

 

Related Articles

  • From the editors.  // Nature Reviews Genetics;Oct2011, Vol. 12 Issue 10, p665 

    An introduction is presented in which the editors discuss various reports within the issue on topics including the relationship between phenotype and genotype, the contributions of silent and non-synonymous mutations on diseases, and a discussion regarding direct-to-consumer genetic testing.

  • Extensive clinical, hormonal and genetic screening in a large consecutive series of 46,XY neonates and infants with atypical sexual development. Baetens, Dorien; Mladenov, Wilhelm; Delle Chiaie, Barbara; Menten, Bj√∂rn; Desloovere, An; Iotova, Violeta; Callewaert, Bert; Van Laecke, Erik; Hoebeke, Piet; De Baere, Elfride; Cools, Martine // Orphanet Journal of Rare Diseases;2014, Vol. 9 Issue 1, p416 

    Background One in 4500 children is born with ambiguous genitalia, milder phenotypes occur in one in 300 newborns. Conventional time-consuming hormonal and genetic work-up provides a genetic diagnosis in around 20-40% of 46,XY cases with ambiguous genitalia. All others remain without a definitive...

  • ironXS: high-school screening for hereditary haemochromatosis is acceptable and feasible. Delatycki, Martin B; Wolthuizen, Michelle; Collins, Veronica; Varley, Elizabeth; Craven, Joanna; Allen, Katrina J; Gurrin, Lyle C; Aitken, Maryanne; Trembath, M Kaye; Bond, Lyndal; Wilson, Gabrielle R; Stephenson, Sarah EM; Macciocca, Ivan; Hickerton, Chriselle; Lockhart, Paul J; Metcalfe, Sylvia A // European Journal of Human Genetics;May2012, Vol. 20 Issue 5, p505 

    As the results of the Human Genome Project are realised, screening for genetic mutations that predispose to preventable disease is becoming increasingly possible. How and where such screening should best be offered are critical, unanswered questions. This study aimed to assess the acceptability...

  • Screening for Hereditary Hemochromatosis: A Clinical Practice Guideline from the American College of Physicians. Qaseem, Amir; Aronson, Mark; Fitterman, Nick; Snow, Vincenza; Weiss, Kevin B.; Owens, Douglas K. // Annals of Internal Medicine;10/4/2005, Vol. 143 Issue 7, p517 

    Hereditary hemochromatosis is a genetic disorder of iron metabolism. Diagnosis of hereditary hemochromatosis is usually based on a combination of various genetic or phenotypic criteria. Decisions regarding screening are difficult because of the variable penetrance of mutations of the HFE gene...

  • Hemochromatosis: Clinical implications of genetic testing. Adams, Paul C. // CMAJ: Canadian Medical Association Journal;07/28/98, Vol. 159 Issue 2, p156 

    Editorial. Discusses genetic testing for the disease Hemochromatosis. Hemochromatosis as a very common disease affecting Canadians; Detection of the disease by a blood test; Reasons of discrepancy of its genetic prevalence; Population screening studies; The problem of the misdiagnosis of...

  • Genetic screening for iron overload: No evidence of discrimination at 1 year. Hall, Mark A.; Barton, James C.; Adams, Paul C.; McLaren, Christine E.; Reiss, Jacob A.; Castro, Oswaldo; Ruggiero, Andrea; Acton, Ronald T.; Power, Tara E.; Bent, Thomas C. // Journal of Family Practice;Oct2007, Vol. 56 Issue 10, p829 

    The article presents a study which assesses the extent of insurance and employment problems associated with population screening involving 101,168 primary care patients from the U.S. and Canada for iron phenotypes and hemochromatosis gene (HFE) genotypes associates with hemochromatosis. A...

  • Is BRCA 1/2 genetic testing cost effective in the USA?  // PharmacoEconomics & Outcomes News;1/21/2012, Issue 645, p6 

    The article reports on the findings by researchers from the University of Rochester School of Medicine that BRCA 1/2 genetic testing of women at high risk of carrying the BRCS 1 or 2 gene mutations, and treatment of those who test positive, seems to be cost effective compared with no genetic...

  • How genetic tests are done.  // Humanities;Mar/Apr97, Vol. 18 Issue 2, p38 

    Discusses how two types of genetic tests are done. Direct test; Linkage test; Test that recognizes tiny alterations or mutations in the DNA of a gene.

  • Should asymptomatic haemochromatosis be treated? Seamark, Clare J // BMJ: British Medical Journal (International Edition);05/13/2000, Vol. 320 Issue 7245, p1314 

    Discusses issues associated with the diagnosis and treatment of hereditary haemochromatosis. Description of a general practitioner's experience in the treatment of asymptomatic haemochromatosis; Patient's view on the treatment process; Genetic screening for the disease; Trial evidence on the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics